In a report launched right now, Jason Butler from JMP Securities reiterated a Purchase score on PLx Pharma (PLXP – Analysis Report), with a worth goal of $21.00. The corporate’s shares closed final Friday at $12.31.
In accordance with TipRanks.com, Butler is a 3-star analyst with a mean return of 4.1% and a 42.8% success price. Butler covers the Healthcare sector, specializing in shares comparable to Utilized Molecular Transport, Aquestive Therapeutics, and ACADIA Prescribed drugs.
PLx Pharma has an analyst consensus of Average Purchase, with a worth goal consensus of $25.00.
See Insiders’ Sizzling Shares on TipRanks >>
Primarily based on PLx Pharma’s newest earnings launch for the quarter ending June 30, the corporate reported a quarterly GAAP web lack of $16.5 million. Compared, final yr the corporate earned income of $27.91K and had a GAAP web lack of $5.6 million.
TipRanks has tracked 36,000 firm insiders and located that a couple of of them are higher than others on the subject of timing their transactions. See which 3 shares are almost certainly to make strikes following their insider actions.
PLx Pharma, Inc. is a late-stage specialty pharmaceutical firm, which engages within the improvement of clinically validated and patent-protected PLxGuard supply system. Its merchandise embrace Vazalore 325 mg and PL1200 Ibuprofen 200 mg. The corporate was based by Ronald R. Zimmerman on November 12, 2002 and is headquartered in Houston, TX.
Learn Extra on PLXP: